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Abstract
Background: Midazolam is commonly used as a pre-anesthesia anxiolytic. It`s elimination may not be fast enough
for short procedures. In orally premedicated patients we obtained midazolam plasma concentrations at the end of
surgical procedures and compared those to concentrations at anesthesia induction.
Methods: The study was conducted prospectively with consent of the local ethics committee (Ethikkomission
Kanton Thurgau, Switzerland) and carried out with written informed consent of each patient. Female patients aged
20 to 60 years undergoing elective procedures with general anesthesia were included, and were divided in two
groups according to the planned surgical time: group S (<30 min) and group L (90–120 min), respectively. All patients
received 7.5 mg Midazolam po as premedication. Blood samples were drawn at anesthesia induction, and at the end
of surgery. Data were compared with t-test (independent samples; significance level p <0.05).
Results: Twenty-five patients per group were included. Four patients were excluded from analysis, since midazolam
was not detectable in any samples. Time of premedication to the 1st blood sample was not statistically different between
groups, neither were Midazolam plasma levels at this time point (p = 0.94). None of the patients from group L (n = 24),
but five patients in group S (n = 22) did have a higher plasma level of Midazolam at the end of the case compared to
the beginning.
Conclusions: The elimination half-life of oral Midazolam can lead to higher plasma levels at the end of a short
procedure compared to those at induction of anesthesia.
Trial registration: German Clinical Trials Register (Deutsches Register Klinischer Studien), DRKS00005429; date of
registration 3rd January 2014
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Background
In our institution, for many years Midazolam has been
the premedication drug of choice for anxiolysis in pa-
tients undergoing general anesthetics.
Generally, the standard dosage for Midazolam used as an
oral premedication before general anesthesia is 7.5–15 mg
in adults [1]. The drug is usually administered about 30 to
45 min before transporting the patient to the operating
room. In clinical practice, this setup has worked in a
reliable fashion. Surprisingly, there is no published data
on resulting plasma levels of midazolam at induction of
anesthesia or at the end of surgical procedures.
This may be an issue because of the rather long elim-
ination half-life of 90–150 min that possibly could result
in a comparatively long sedative effect of midazolam.
Further, in daily routine, it is not clear, when the peak of
absorption actually occurs in relation to the anesthetic
process. This can potentially contribute to relatively high
plasma levels of midazolam at the end of short proce-
dures and therefore lead to delayed and prolonged emer-
gence from the anesthetic.
In the present study we determined midazolam plasma
levels in an everyday clinical setting at the time of induc-
tion of anesthesia and at the end of the surgical procedure
in procedures of different durations. The study attempted
to validate the hypothesis that some patients receiving oral
midazolam premedication will show higher plasma levels
at the end of short procedures (<30 min) compared to the
levels determined just before induction of anesthesia. In
contrast, patients undergoing longer procedures (> 1.5 h)
will always have lower midazolam levels at the end of
anesthesia compared to levels measured just before induc-
tion of anesthesia.
Methods
This study was conducted prospectively with the approval
of the local ethics committee (Ethikkomission des Kantons
Thurgau, Switzerland; May 2013) and after registration
with the German Clinical Trials Register (www.drks.de;
DRKS00005429). All study participants were informed be-
forehand and gave their written consent.
Inclusion criteria were scheduled gynecological surgery
under general anesthesia, age between 20 and 60 years,
7.5 mg midazolam po clinically indicated according to
the standard of our institution and patient consented
prior to the procedure. We excluded patients with the
following conditions: allergy or hypersensitivity to benzodi-
azepines, severe respiratory insufficiency, myasthenia gravis,
sleep apnea syndrome, compromised renal and or hepatic
function, psychiatric conditions, pregnancy, lactation, alco-
hol abuse, iv drug abuse, medication with antifungals/ anti-
virals/ protease inhibitors/ macrolides/ rifampin/ calcium
channel blockers/ antihistamines/ St. John's wort/ tranquil-
izers/ sedatives/ hypnotics/ antidepressants/ antiepileptics
in the week before surgery, consumption of grapefruit juice
on the day of or before surgery, BMI > 40 kg/m2, pre-
existing conditions with impaired gastrointestinal absorp-
tion, additional midazolam given during procedure.
Patients were fasted 6 hours for solid food and two
hours for clear liquid prior to the planned induction of
anesthesia.
A total of 50 patients (25 each with a planned operating
time of ≤ 30 min (group S), and 90–120 min (Group L),
respectively) were given 7.5 mg midazolam po (Dormi-
cum©; Roche Ltd., 4253 Reinach, Switzerland) before they
were transported to the operating room. The order was
called to the ward from the operating room by anesthesia
providers that were not part of the study group. In accord-
ance to the standard practice for patients receiving general
anesthesia at our institution, the premedication with mid-
azolam po ideally would take place 30 to 45 min before
the patient came to the operating room. For the study pa-
tients, the time when the po midazolam was given on the
ward was recorded.
The anesthesiologist that managed the operating room
coordinated the patient flow to the operating room. As a
governing principle, we try to have the patient waiting
not too long in the operating room holding area; on the
other hand we aim to have short room turnover times
doing regular overlapping anesthesia inductions. The ar-
rival of the patient to the operating room is routinely
documented on the anesthesia record.
On arrival to the operating room, the patient’s level of
sedation was assessed by one of the investigators using
the OAA/S score (Observer’s Assessment of Alertness/
Sedation score; reported as the composite score with
OAA/S ranging from 1 [deep sleep] to 5 [alert]) [2]. The
OAA/S assesses responsiveness of a given subject to its
name, spoken in normal tone, calling loudly or repeat-
edly, followed by shaking of the subject, respectively. Re-
sponsiveness is classified taking into account speech,
facial expression and eye opening.
For the general anesthetic, we placed the standard
monitoring first (ECG, non-invasive blood pressure
measurement, pulse oximetry, BIS [Bispectral index; BIS
View, Covidien, Dublin, Ireland; EEG assessment using
the bispectral index]), an initial set of values was re-
corded, before moving on and establishing peripheral
venous access on the back of the hand or forearm. While
placing the venous cannula, 5 ml of blood were collected
in a serum tube. The time of blood collection was re-
corded (time point 1).
The further course of anesthesia mainly was a Propofol
based anesthesia, supplemented with fentanyl and remi-
fentanil. Anesthesia conduct was left to the responsible
anesthetist, according to the standard of our institution.
At the end of the surgical procedure, before emerging
from the anesthesia, a second blood sample (5 ml, serum
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tubes) was drawn from the opposite arm, and the time
was noted (time point 2).
Both serum tubes were labeled and properly stored in the
laboratory of our hospital (Kantonsspital Frauenfeld). After
completion of the entire study all the samples were sent to
the Institute of Clinical Chemistry of the University Hos-
pital Zurich (http://www.usz.ch) where the plasma levels of
midazolam were determined by liquid chromatography-
mass spectrometry (LC-MS). After addition of stable-
isotope labelled internal standards, samples were centri-
fuged. Twenty microliters of the clear supernatant was sub-
mitted to the analysis using a turbulent flow online
extraction system. As extraction column, a Cyclone col-
umn (Thermo Fisher, Reinach, Switzerland; 50 × 0.5 mm)
was used, as analytical column, a Uptisphere C18 (125 ×
2 mm). The mobile phases consisted of 10 mM ammo-
nium acetate in water + 0.1 % formic acid and 10 mM
ammonium acetate in methanol/acetonitrile 50/50 (v/v) +
0.1 % formic acid. Calibration was done using an in-
house prepared six point calibration curve. The method
is validated and has an imprecision of less than 5.3 %.
The quantification limit is at 0.01 mcmol/l.
On the day after surgery, the patients were asked to
rate their level of satisfaction with the overall effect of
the preoperative po midazolam on a visual analogue
scale (VAS 0-10; 0 = totally dissatisfied, 10 = completely
satisfied).
Statistics
All data (midazolam plasma levels etc.) are presented de-
scriptively as mean ± standard deviation, BIS values and
sedation scores are presented as median (minimum -
maximum).
Comparisons between group S and group L were made
using the t test for independent samples, and using the
Mann-Whitney U-test for BIS values and sedation scores.
The statistical evaluations were performed using
Microsoft Excel 2010 (Microsoft, Redmond, USA), and
StatView 5.0.1 (SAS Institute, Cary NC, USA).
As there are no data about midazolam plasma levels at
the end of anesthetics and the main outcome of our
study was the number of patients with higher midazolam
plasma levels at the end of anesthesia compared to
anesthesia induction, there was no formal power analysis
performed.
Results
Fifty patients were enrolled in this study (25 for each
group). Four patients (three in group S and one in group L)
were excluded from the statistical analysis, because neither
midazolam, nor its metabolite 1-OH-midazolam were
detectable in any blood samples, and we assumed that the
patients have not taken the medication.
The demographic data of the patients are summarized
in Table 1. All patients except for one (group L) were
classified as ASA physical status I or II.
The timespan between taking the midazolam po and
the 1st blood sample was 63.9 ± 31.4 min in group S and
52.6 ± 18.1 min in group L (p = 0.12). In accordance with
the study protocol, the time between premedication and
the second blood sample was significantly shorter in group
S (112.2 ± 35.1 min) than in Group L (165.4 ± 44.5 min;
p = 0.0002).
The O/AAS values upon arrival in the operating
room differed very little between group S (4.2 ± 0.7)
and Group L (4.1 ± 0.7; p = 0.81) as did the first mea-
sured BIS values (94.5 ± 4.1 in group S and 95.9 ± 3.2 in
group L; p = 0.28).
In the first blood sample the midazolam plasma
levels were similar in both groups (0.10 ± 0.07 mcmol/
l in group S, 0.10 ± 0.06 mcmol/l in group L; p = 0.94).
In the second blood sample at the end of the surgical
procedure, the midazolam plasma levels in group S
(0.06 ± 0.04 mcmol/l) were significantly higher than in
group L (0.02 ± 0.02 mcmol/l; p = 0.01).
Surgery was exclusively gynecological, comprising
mostly curettage, hysteroscopy, and biopsies in Groups
S, and vaginal hysterectomy with or without uro-
gynecological surgery, and breast surgery in Group L.
In none of the patients in group L (n = 24) was the mid-
azolam plasma level higher at the end of surgery than be-
fore induction of anesthesia, whereas five patients of the
Table 1 Demographic data (mean ± standard deviation); p = t-test or Mann-Whitney U-test, as appropriate
Gruppe S Gruppe L p
Age (years) 38.5 (± 11.3) 44.4 (± 12.6) 0.08
Height (centimeters) 164.2 (± 4.9) 166.5 (± 6.2) 0.16
Weight (kg) 63.4 (± 11.3) 70.2 (±12.8) 0.21
BMI (kg/m2) 23.5 (± 4.4) 25.3 (± 4.5) 0.3
Midazolam dose (mg per kg) 0.12 (± 0.02) 0.11 (±0.02) 0.14
BIS values at arrival in OR (0–100) 94.5 (± 4.1) 95.9 (± 3.2) 0.28
Mean duration of surgical procedure (min) 20.4 (± 12.8) 79.8 (± 36.5) <0.0001
Level of satisfaction (VAS; 0–10) 8.2 (± 1.8) 8.3 (± 1.6) 0.69
BMI Body mass index, BIS Bisoectral index, OR operating room
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group S (n = 22) did have an increased plasma level at
the end of the case compared to the pre procedure
value (see Figs. 1 or 2).
Excluding the five patients with higher midazolam
plasma levels at the end of surgery from group S, plasma
levels in group S remained significantly higher than in
group L (0.05 ± 0.03 mcmol/l versus 0.02 ± 0.02 mcmol/l;
p = 0.01).
The satisfaction VAS score did not differ significantly
between the two groups (8.2 ± 1.8 in group S and 8.3 ± 1.6
in group L; p = 0.69).
Discussion
In this study, midazolam po pharmaceutical premedica-
tion was used in patients undergoing general anesthesia
for gynecological procedures. The resulting plasma levels
at the time of anesthesia induction were compared to
those at the end of the surgical procedure.
The main finding of this study was that in the group
of patients that underwent shorter procedures (planned
surgical time less than 30 min), a substantial percentage
had higher midazolam plasma levels at the end of the
operation compared to the time of anesthesia induction.
In the group of patients with a longer duration of sur-
gery (90–120 min), all patients had lower midazolam
levels at the end of the procedure.
Midazolam serves as a very common choice to achieve
anxiolysis in children, adolescents and adults before
anesthesia [1, 3, 4]. While children often receive rela-
tively high doses, the standard dosage for adults, if
administered po, ranges just around 7.5–15 mg [1]. The
reason for this, instead of dosing in relation to body
weight might be, that midazolam most commonly is
available in tablets of these quantities. However, neither
the reliability of midazolam induced sedation, nor the
duration of action of midazolam premedication are with-
out debate.
The optimal time point for the administration and
dosing of midazolam preoperatively remains unclear and
appears to be individually different. According to the
study by Lim the sedative effects started to wear off after
45–60 min from the time point when midazolam was
given as a tablet [5].
In our study it took 48 min from the time of applica-
tion of the drug to the first pre-operative blood sample.
For some individual patients the peak sedative effect
could have already happened before they actually came
to the operating room.
In addition, the interindividual metabolism of midazo-
lam can differ greatly. After oral administration of 15 mg
po in young, healthy people its bioavailability varies
between 30 and 50 %, and the elimination half-life is be-
tween 1.5 and 2.5 h [6]. A comparative study with par-
ticipants from five different ethnic Chinese groups also
demonstrated large differences between these [7]. So,
apart from the fixed dose, differences in timing of
anesthesia premedication, varying resorption and metabol-
sing of the drug, as well as genetic factors contribute to
the high variability of resulting plasma concentracions
seen in this study under clinical routine conditions.
Fig. 1 Trend of midazolam plasma levels (mcmol/l) in group S. 1 = before anesthesia induction, 2 = end of surgery
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The patients in our study were consistently medicated
with 7.5 mg midazolam po. As this study was designed
to assess clinical routine, this fixed dose was chosen, in-
stead of dosing in relation to body weigth. This resulted
in moderate midazolam plasma levels. The reported
mean of 0.11 (± 0.06) micromol/l is corresponding to
about 30 ng/ml. In the Swiss Drugs registry (http://
www.compendium.ch), 7.5 to 15 mg midazolam PO is
given as the standard dosing for anesthesia premedica-
tion. The laboratory of our institution regards 0.3 to 1
micromol/l as therapeutic plasma level, however without
differentiating for which indication. Accordingly, both
the subjectively and objectively detectable sedative effect
preoperatively was only moderate, but at the same time
the subjective satisfaction was rather good. OAA/S
scores and BIS values at arrival in the operating room
showed only a narrow variation, meaning the effect of
the premedication being fairly predictable.
Even when higher doses are given, the sedative effect
of midazolam often appears to be only modest and/or
hard to quantify both in older children and adults on ar-
rival to the operating room and immediately before
anesthesia induction. Brosius et al. describe adolescents
who received 20 mg midazolam po, as having a BIS
value of 92 immediately before induction of anesthesia
with an OAA/S sedation score indicating a relevant level
of sedation in only 40 % of the patients [4]. This may
partially be explainable by the fact that entering the op-
erating room and attaching the monitoring to the pa-
tient with the imminent beginning of anesthesia and
surgery probably represents the moment of greatest
stress and nervousness. Oral intake of midazolam as a
tablet also leads to a lower sedative effect compared to
sublingual application of the same dose, because of
bypassing the first-pass effect in the liver. Various drug
compounds are also likely to play a role. Lim et al. have
shown that it can take up to 20 min, until a Dormicum©
tablet is completely dissolved in the mouth [5].
The plasma levels that we measured seem very low
compared to what is reported in pediatric anesthesia
publications. However, for example in Brosius and Bann-
ister’s study, resulting in much higher plasma levels,
adolescent patients were only about 10 % lighter on
average and received almost a 3-fold dose of midazolam
than compared to our setting [4].
All the above mentioned points add to our main find-
ing that under clinical routine conditions some patients
having been orally premedicated with Dormicum© be-
fore short surgical procedures, had higher plasma levels
of the drug at the end of their procedure (when expected
to awake from the anesthetic) compared to the induction
of anesthesia when anxiolysis and sedation were most
desirable.
Brosius and Bannister were not able to show an inter-
action of midazolam with general anesthetics (Sevoflur-
ane-based) in their setting and the recovery period after
a standardized anesthetic in their midazolam group
compared with a placebo group was not significantly
longer [4, 8]. However, in settings like e.g. ambulatory or
office based anesthetics, the rather long half-life of
Fig. 2 Course of midazolam plasma levels (mcmol/l) in group L. 1 = before anesthesia induction, 2 = end of surgery
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midazolam induced sedation might be of concern. If
only intended for providing preoperative anxiolysis and
not added as medication for maintaining the anesthetic,
a reliably performing, shorter acting anxiolytic could be
a more suiting companion for this purpose. If preferring
a benzodiazepine, remimazolam may in the future be an
interesting option [9].
Our study setup had some limitations. The actual in-
take of the midazolam tablet on the ward happened
largely unsupervised. The fact that four patients had no
detectable plasma levels for neither midazolam nor its
metabolites could be the result from the patients not
having actually taken the tablet. It is also conceivable
that some patients may have ingested only fractions of
the actual tablet. Furthermore, it would have been very
interesting to correlate the midazolam plasma levels at
the end of the procedure with the time it took to emerge
from anesthesia. In order to do so, the anesthetic man-
agement would have needed standardization with a
protocol, which was not the case in our study. Also, if
correlating midazolam plasma levels to clinical effect, it
might be necessary to consider levels of α-hydroxy-
midazolam, a metabolite with intrinsic action. However,
the midazolam plasma levels in our study were quite
low, and therefore most probably not significantly influ-
encing emerging times after anesthesia.
Finally, dosing in relation to body weight might lead to
more reliable plasma concentrations, but is not practic-
able with standard Dormicum© tablets.
The results of this study might lead the anesthesiologist
to reconsider the use of standard, rather long acting
midazolam premedication in patients undergoing surgery
with a planned duration of less than 30 min. Non-
pharmacological anxiolysis or new, shorter acting sub-
stances may be the solution to this problem.
Conclusions
In summary, the most pertinent finding in this study
was the fact that midazolam po as an anxiolytic before
general anesthesia in short interventions can result in
higher plasma levels at the end of the procedure.
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